Evidence map›Paper›PMID 24889511›Full record

ArticleLeukemia research2014

Genomic aberrations deletion 11q and deletion 17p independently predict for worse progression-free and overall survival after allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia.

Julio C Chavez, Mohamed A Kharfan-Dabaja, Jongphil Kim, Binglin Yue, Samir Dalia, Javier Pinilla-Ibarz, Claudio Anasetti, Frederick L Locke

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Julio C ChavezDepartment of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, USA.
Mohamed A Kharfan-DabajaDepartment of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center, Tampa, USA; Department of Oncologic Sciences, University of South Florida, Tampa, USA.
Jongphil KimDepartment of Biostatistics and Biomedical Sciences, H. Lee Moffitt Cancer Center, Tampa, USA.
Binglin YueDepartment of Biostatistics and Biomedical Sciences, H. Lee Moffitt Cancer Center, Tampa, USA.
Samir DaliaDepartment of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, USA; Department of Oncologic Sciences, University of South Florida, Tampa, USA.
Javier Pinilla-IbarzDepartment of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, USA; Department of Oncologic Sciences, University of South Florida, Tampa, USA.
Claudio AnasettiDepartment of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center, Tampa, USA; Department of Oncologic Sciences, University of South Florida, Tampa, USA.
Frederick L LockeDepartment of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center, Tampa, USA; Department of Oncologic Sciences, University of South Florida, Tampa, USA. Electronic address: frederick.locke@moffitt.org.
Moffitt Cancer Center · US

Funding

TRANSLATIONAL RESEARCHP30CA076292 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI KENNETH Lynn WRIGHT · 1998 to 2026
$93.5M
NCI NIH HHS P30 CA076292
6 · The paper itself

Abstract

Chronic lymphocytic leukemia remains incurable despite availability of potent chemoimmunotherapy regimens. Allogeneic hematopoietic cell transplantation (HCT) is the only modality that offers the possibility of cure. To identify predictors of progression-free and overall survival, we evaluated outcomes of 43 consecutive patients who received an allograft for advanced CLL. The majority received a reduced intensity conditioning regimen (n=37). Donors were HLA matched-related (n=18), matched-unrelated (n=15), mismatched-unrelated (n=7), or umbilical cord blood (n=3). The median progression-free (PFS) and overall survival (OS) were 31.4 months and 46.4 months respectively. Twenty (46.5%) patients were alive and in complete remission at a median follow-up of 31.4 months. NRM was higher than previously published series for CLL, likely due to a high burden of comorbidity (22 patients with HCT-CI ≥ 2) and a high proportion receiving HLA mismatched-unrelated donor or umbilical cord blood cells. Presence of del (11q), del(17p), or progressive disease at HCT are independent predictors of worse PFS and OS. New strategies are needed to improve survival outcomes in CLL associated with poor risk cytogenetics.

Indexed as

Chromosomes, Human, Pair 11Chromosomes, Human, Pair 17Hematopoietic Stem Cell TransplantationAdultAgedDisease-Free SurvivalFemaleGene DeletionGenome, HumanHumansKaplan-Meier EstimateLeukemia, Lymphocytic, Chronic, B-CellMaleMiddle AgedPrognosisRetrospective Studies11q deletion17p deletionAllogeneic hematopoietic cell transplantCLLGenomic aberrationsOutcomes

Identifiers

PMID24889511
PMCPMC4625795
OpenAlexW2014776940

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.